SCARB2 and hepatocellular carcinoma: Furthermore, loss of SCARB2 decreased the median inhibitory concentration (IC50) of sorafenib in HCC cells, which suggested that SCARB2 knockout sensitized HCC cells to sorafenib (Fig. 1k).